Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
This study is currently recruiting participants.
Verified January 2013 by Memorial Sloan-Kettering Cancer Center
Study NCT01323517
Information provided by Memorial Sloan-Kettering Cancer Center
First Received on March 23, 2011.
Last Updated on January 3, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
